Onkologie. 2023:17(5):329-334 | DOI: 10.36290/xon.2023.062

Current treatment options for BRAF V600E mutant metastatic colorectal cancer

Marián Liberko1, 2, Renata Soumarová1, 2
1 Onkologická klinika, 3. LF UK a FNKV, Praha
2 3. lékařská fakulta, Univerzita Karlova, Praha

Metastatic colorectal cancer (mCRC) is a heterogenous disease, in which prognosis of patients depends largely on presence/absence of specific prognostic and predictive markers. BRAF (v-raf murine sarcoma viral oncogene homolog B) V600E mCRC, relatively small subgroup of mCRC, is characterised by high biological aggressiveness and short term survival when compared to other subtypes of mCRC. Review provides an overview about biology of this subtype, treatment options and recent advancements in targeted therapy.

Keywords: BRAF V600E, metastatic colorectal cancer, systemic treatment, FOLFOXIRI, encorafenib, cetuximab.

Accepted: November 28, 2023; Published: November 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Current treatment options for BRAF V600E mutant metastatic colorectal cancer. Onkologie. 2023;17(5):329-334. doi: 10.36290/xon.2023.062.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338. Go to original source... Go to PubMed...
    2. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322-5330. doi: 10.1158/1078-0432.CCR-14-0332. Epub 2014 Aug 19. PMID: 25139339; PMCID: PMC4201568. Go to original source... Go to PubMed...
    3. Seligmann JF, Fisher D, Smith CG, et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2017;28(3):562-568. doi: 10.1093/annonc/mdw645. PMID: 27993800. Go to original source... Go to PubMed...
    4. Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastro­intest Oncol. 2015;6(6):660-667. doi: 10.3978/j.issn.2078-6891.2015.077. PMID: 26697199; PMCID: PMC4671844. Go to original source... Go to PubMed...
    5. Jones JC, Renfro LA, Al-Shamsi HO, et al. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9. PMID: 28486044; PMCID: PMC5549454. Go to original source... Go to PubMed...
    6. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787-793. doi: 10.1038/ng1834. Epub 2006 Jun 25. PMID: 16804544. Go to original source... Go to PubMed...
    7. Další literatura u autora a na www.onkologiecs.cz
    8. Schirripa M, Biason P, Lonardi S, et al. Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clin Cancer Res. 2019;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9. PMID: 30967421. Go to original source... Go to PubMed...
    9. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. doi: 10.1038/nm.3967. Epub 2015 Oct 12. PMID: 26457759; PMCID: PMC4636487. Go to original source... Go to PubMed...
    10. Barras D, Missiaglia E, Wirapati P. BRAF V600E Mutant Colo­rectal Cancer Subtypes Based on Gene Expression. Clin Can­cer Res. 2017;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27. PMID: 27354468. Go to original source... Go to PubMed...
    11. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643-2648. doi: 10.1158/0008-5472.CAN-06-4158. PMID: 17363584. Go to original source... Go to PubMed...
    12. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-5712. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10. PMID: 19001320. Go to original source... Go to PubMed...
    13. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535-1546. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12. PMID: 21228335. Go to original source... Go to PubMed...
    14. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009;101(4):715-721. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14. PMID: 19603018; PMCID: PMC2736831. Go to original source... Go to PubMed...
    15. Stintzing S, Miller-Phillips L, Modest DP, et al. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer. 2017;79:50-60. doi: 10.1016/j.ejca.2017.03.023. Epub 2017 Apr 29. PMID: 28463756. Go to original source... Go to PubMed...
    16. Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888-1894. doi: 10.1038/bjc.2015.173. Epub 2015 May 19. PMID: 25989278; PMCID: PMC4580381. Go to original source... Go to PubMed...
    17. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-3506. doi: 10.1200/JCO.2012.42.8201. Epub 2012 Sep 4. PMID: 22949147. Go to original source... Go to PubMed...
    18. Yoshino T, Portnoy DC, Obermannová R, et al. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol. 2019;30(1):124-131. doi: 10.1093/annonc/mdy461. PMID: 30339194; PMCID: PMC6336001. Go to original source... Go to PubMed...
    19. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal can­cer. N Engl J Med. 2014;371(17):1609-1618. doi: 10.1056/NEJMoa1403108. PMID: 25337750. Go to original source... Go to PubMed...
    20. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306-1315. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31. PMID: 26338525. Go to original source... Go to PubMed...
    21. Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. PMID: 32164906. Go to original source... Go to PubMed...
    22. Cremolini C, Antoniotti C, Stein A, et al. J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Epub ahead of print. PMID: 32816630. Go to original source... Go to PubMed...
    23. Martinelli E, Cremolini C, Mazard T, et al. Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open. 2022;7(6):100603. doi: 10.1016/j.esmoop.2022.100603. Epub 2022 Nov 8. PMID: 36368253; PMCID: PMC9832736. Go to original source... Go to PubMed...
    24. Moretto R, Giordano M, Poma AM, et al. Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. Eur J Cancer. 2021;153:16-26. doi: 10.1016/j.ejca.2021.04.039. Epub 2021 Jun 12. PMID: 34126333. Go to original source... Go to PubMed...
    25. Moretto R, Elliott A, Rossini D, et al. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? Br J Cancer. 2022;127(5):957-967. doi: 10.1038/s41416-022-01852-0. Epub 2022 Jun 3. PMID: 35665778; PMCID: PMC9428147. Go to original source... Go to PubMed...
    26. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-736. doi: 10.1056/NEJMoa1502309. Erratum in: N Engl J Med. 2018;379(16):1585. PMID: 26287849; PMCID: PMC4971773. Go to original source... Go to PubMed...
    27. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-1901. doi: 10.1016/S0140-6736(12)60398-5. PMID: 22608338; PMCID: PMC4109288. Go to original source... Go to PubMed...
    28. Gomez-Roca CA, Delord J, Robert C, et al. NoEncorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion in an open-label, phase 1 study. Ann Oncol. 2014;25:iv182-iv183(suppl 4; abstr 535P). Go to original source...
    29. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2(3):227-235. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16. PMID: 22448344; PMCID: PMC3308191. Go to original source... Go to PubMed...
    30. Prahallad A, Sun C, Huang S, Di Nicolantonio F, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103. doi: 10.1038/nature10868. PMID: 22281684. Go to original source... Go to PubMed...
    31. Kopetz S, Guthrie KA, Morris VK, et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23. PMID: 33356422; PMCID: PMC8462593. Go to original source... Go to PubMed...
    32. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. PMID: 31566309. Go to original source... Go to PubMed...
    33. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39(4):273-284. doi: 10.1200/JCO.20.02088. PMID: 33503393; PMCID: PMC8078423. Go to original source... Go to PubMed...
    34. Kopetz S, Murphy DA, Pu J, et al. Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. J Clin Oncol. 2021;39:15s(suppl; abstr 3513). Go to original source...
    35. Elez E, Ros J, Fernández J, et al. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022;28(10):2162-2170. doi: 10.1038/s41591-022-01976-z. Epub 2022 Sep 12. PMID: 36097219; PMCID: PMC9556333. Go to original source... Go to PubMed...
    36. Van Cutsem E, Taieb J, Yaeger R,et al. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. J Clin Oncol. 2023;41(14):2628-2637. doi: 10.1200/JCO.22.01693. Epub 2023 Feb 10. PMID: 36763936; PMCID: PMC10414717. Go to original source... Go to PubMed...
    37. Tabernero J. LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). Annals of Oncology. 2022;(33):S1392-S1393. Go to original source...
    38. Corcoran R, Giannakis M, Allen J, et al. Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Ann Oncol. 2020;31:S226-S227(suppl 3; abstr SO-26). Go to original source...
    39. SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). Kopetz CK, Tanios S, et al. Journal of Clinical Oncology 2022 40:16_suppl: TPS3634-TPS3634. Go to original source...
    40. Morris VK, Parseghian CM, Escano M, et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF V600E metastatic colorectal cancer. J Clin Oncol. 2022;40:4s(suppl 4; abstr 12). Go to original source...
    41. Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14. PMID: 31725351; PMCID: PMC7031958. Go to original source... Go to PubMed...
    42. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20. PMID: 29355075. Go to original source... Go to PubMed...
    43. André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. PMID: 33264544. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.